Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02343523 · ClinicalTrials.gov registry record
Pilot Study of the QI Device for Monitoring of Patients With Congestive Heart Failure
A clinical trial, sponsored by Scripps Translational Science Institute.
- Completed
- Registry status
- 13
- Enrollment target
NCT02343523: Completed study, sponsored by Scripps Translational Science Institute.
NCT02343523 is a clinical trial that has completed, run by Scripps Translational Science Institute. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02343523 has completed, sponsored by Scripps Translational Science Institute.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
Study Summary
The present study proposes to utilize a novel, wearable device, QI Device, which has multiple sensors embedded in a "wrist-watch" in order to explore its monitoring capabilities in individuals with congestive heart failure.
Primary Outcome
Phase 1: Will include hospitalized patients admitted to the hospital with a clinical diagnosis of ADHF. Phase 2: Will include patients being discharged from the hospital with a primary clinical diagnosis of ADHF and will be monitored for up to 30 days following hospitalization.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-09 |
What the finished NCT02343523 record still lists
NCT02343523 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02343523 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02343523 about?
NCT02343523 is a clinical study titled "Pilot Study of the QI Device for Monitoring of Patients With Congestive Heart Failure". The present study proposes to utilize a novel, wearable device, QI Device, which has multiple sensors embedded in a "wrist-watch" in order to explore its monitoring capabilities in individuals with congestive heart failure.
What is the current status of trial NCT02343523?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2015-01. Estimated completion is 2015-09.
Who is sponsoring clinical trial NCT02343523?
This trial is sponsored by Scripps Translational Science Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia